New study challenges the concept of treatment failure in hepatitis C

April 16, 2016
Electron micrographs of hepatitis C virus purified from cell culture. Scale bar is 50 nanometers. Credit: Center for the Study of Hepatitis C, The Rockefeller University.

Data presented today demonstrate that choosing a different combination of direct-acting antiviral (DAA) treatment for Hepatitis C can eradicate the virus at four weeks in patients who had already failed on previous medication regimens.

The results were presented at The International Liver Congress in Barcelona, Spain and suggest that with the amount of DAAs available, the right combinations must be chosen for the right patients in order to eradicate the virus from the body.

Between 130 and 150 million people globally have chronic Hepatitis C virus (HCV) infection.1 It is estimated that 15 million people in the World Health Organization's EU Region are living with Hepatitis C, representing 2% of adults.2 Direct-acting antivirals are the treatment of choice for HCV, and these medicines have been used to treat and cure almost all patients.3,4,5,6

"As a result of the emergence of resistance associated variants, the re-treatment of patients with HCV remains challenging," said Dr Johannes Vermehren, Universitätsklinikum Frankfurt, Germany and lead author of the study. "While treatment failure was observed in all of the various medication regimens, there is hope for these patients that re-treatment with differing combinations can be effective."

The German study drew patients with failure to DAAs from a large European HCV DAA-resistance database made up of more than 3,500 patients. Patients were included if they had received interferon-free DAA regimens. Treatment combinations were specific to HCV genotype.

The study identified 310 patients with failure to direct-acting antivirals. Among patients with genotype 1 and 3, 84% and 42% had developed resistance associated variants (RAVs), respectively.

Re-treatment was started in 29% (n=57/195) of patients with genotype 1; the majority of these patients had failed treatment with the combination of simeprevir and sofosbuvir, and were re-treated with the combinations of ledipasvir and sofosbuvir or paritaprevir, ombitasvir, and dasabuvir. SVR12 was achieved in 90% of the re-treated patients with genotype 1. In the genotype 3 group, 23% (n=16/69) of patients were re-treated with sofosbuvir, daclatasvir ± ribavirin. All of the re-treated with available follow-up achieved SVR12.

"The concept of failed Hepatitis C may be increasingly out of date. It may indicate that we have not yet found the right combination of drugs to eradicate the virus in a particular patient. With the plethora of direct-acting antivirals available, the medical community must work to find the right combination of medicines for the right patient," said Professor Frank Tacke, member of the EASL Governing Board.

Explore further: Study demonstrates the potential for a new triple combination treatment for hepatitis C patients

More information: References:

1 World Health Organization. Hepatitis C Fact Sheet N°164. Available from: www.who.int/mediacentre/factsheets/fs164/en/. Last accessed: February 2016.
2 World Health Organization. Global Alert and Response - Hepatitis C. Available from: www.who.int/csr/disease/hepati … o2003/en/index3.html. Last accessed: March 2016.
3 1 Afdhal N, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014 May 15;370(20):1889-98.
4 Afdhal N, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014 Apr 17;370(16):1483-93.
5 Kowdley KV, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014 May 15;370(20):1879-88.
6 Sulkowski MS, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014 Jan 16;370(3):211-21.

Related Stories

Study demonstrates the potential for a new triple combination treatment for hepatitis C patients

April 14, 2016
A new combination treatment for hepatitis C has potential for patients who were not cured by current treatment options.

New triple drug combination shows promise in hepatitis C infected patients

April 14, 2016
New data presented today at The International Liver Congress 2016 in Barcelona, Spain, demonstrates a high sustained virologic response (SVR) at 12 weeks from the all-oral combination of sofosbuvir/velpatasvir and experimental ...

Differing perspectives on antiviral treatment efficacy in patients co-infected with HIV and HCV

April 13, 2016
Two separate studies presented today at The International Liver Congress 2016 in Barcelona, Spain have offered alternative conclusions regarding the efficacy of direct-acting antivirals (DAAs) among patients co-infected with ...

Shorter treatment course potentially on the horizon for hep C patients

April 15, 2016
Data from a Phase 2 clinical trial show that an investigational injectable treatment known as RG-101 in combination with a four week course of oral direct-acting antiviral (DAA) treatment was well tolerated and resulted in ...

Newly approved all-oral hep C combination drug found more effective in head-to-head comparison

April 14, 2016
Findings presented today from a Phase 3 head-to-head study that compared two direct-acting antiviral treatment regimens, demonstrated that the all-oral, once daily combination of elbasvir and grazoprevir was more effective ...

High rate of cancer recurrence found in certain hepatitis C patients

April 13, 2016
Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer,1 ...

Recommended for you

Researchers report new system to study chronic hepatitis B

July 25, 2017
Scientists from Princeton University's Department of Molecular Biology have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections. ...

Research examines lung cell turnover as risk factor and target for treatment of influenza pneumonia

July 24, 2017
Influenza is a recurring global health threat that, according to the World Health Organization, is responsible for as many as 500,000 deaths every year, most due to influenza pneumonia, or viral pneumonia. Infection with ...

Scientists propose novel therapy to lessen risk of obesity-linked disease

July 24, 2017
With obesity related illnesses a global pandemic, researchers propose in the Journal of Clinical Investigation using a blood thinner to target molecular drivers of chronic metabolic inflammation in people eating high-fat ...

Raccoon roundworm—a hidden human parasite?

July 24, 2017
The raccoon that topples your trashcan and pillages your garden may leave more than just a mess. More likely than not, it also contaminates your yard with parasites—most notably, raccoon roundworms (Baylisascaris procyonis).

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.